Effects of cilomilast, a selective phosphodiesterase 4 inhibitor, on esophageal motility and ph, and orocecal and colonic transit: Two single-center, randomized, double-blind, placebo-controlled, two-part crossover studies in healthy volunteers

Clinical Therapeutics

Volumn 28, Issue 4, 2006, Pages 569-581

  Houghton, Lesley A ^a   Atkinson, Wendy ^a   Whorwell, Peter J ^a   Morris, Julie ^a   Murdoch, Robert D ^b   Cooper, Stephen M ^b   Webber, Dawn M ^b   Walls, Christine M ^b  

^a WYTHENSHAWE HOSPITAL   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

cilomilast; esophageal motility; esophageal pH; phosphodiesterase 4 inhibitor; transit

Indexed keywords

CILOMILAST; MARKER; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; WATER;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INDUCED HEADACHE; DYSPEPSIA; ESOPHAGUS MOTILITY; ESOPHAGUS PH; EXCRETION; FATIGUE; FEMALE; FLUID INTAKE; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; HUMAN; HYDROGEN BREATH TEST; INTESTINE TRANSIT TIME; LOWER ESOPHAGUS SPHINCTER PRESSURE; MALE; NAUSEA; NORMAL HUMAN; PHARYNGITIS; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; SMOOTH MUSCLE CONTRACTION; UNITED KINGDOM; VOMITING;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADULT; AREA UNDER CURVE; CARBOXYLIC ACIDS; CECUM; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ESOPHAGEAL SPHINCTER, LOWER; ESOPHAGUS; FEMALE; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRANSIT; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MANOMETRY; MIDDLE AGED; NITRILES; PHOSPHODIESTERASE INHIBITORS;

EID: 33646878779     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.04.003     Document Type: Article

References (50)

1. Gamble E., Grootendorst D.C., Brightling C.E., et al. Anti inflammatory effects of the Phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 168 (2003) 976-982
2. Profita M., Chiappara G., Mirabella F., et al. Effect of cilomilast (Ariflo) on TNF-alpha, IL 8, and GM-CSF release by airway cells of patients with COPD. Thorax 58 (2003) 573-579
3. Bertolino A., Crippa D., di Dio S., et al. Rolipram versus imipramine in inpatients with major, "minor" or atypical depressive disorder: A double-blind double-dummy study-aimed at testing a novel therapeutic approach. Int Clin Psychopharmacol 3 (1988) 245-253
4. Palfreyman M.N., and Souness J.E. Phosphodiesterase type IV inhibitors. Prog Med Chem 33 (1996) 1-52
5. Spina D. Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease. Drugs 63 (2003) 2575-2594
6. Griswold D.E., Webb E.F., Badger A.M., et al. SB 207499 (Ariflo), a second generation Phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo. J Pharmacol Exp Ther 287 (1998) 705-711
7. Vignola A.M. PDE4 inhibitors in COPD-A more selective approach to treatment. Respir Med 98 (2004) 495-503
8. Torphy T.J., Barnette M.S., Underwood D.C., et al. Ariflo (SB 207499), a second generation Phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: From concept to clinic. Pulm Pharmacol Ther 12 (1999) 131-135
9. Giembycz M.A. Cilomilast: A second generation phospho-diesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 10 (2001) 1361-1379
10. Barnette M.S., Barone F.C., Fowler P.J., et al. Human lower oesophageal sphincter relaxation is associated with raised cyclic nucleotide content. Gut 32 (1991) 4-9
11. Barnette M.S., Manning C.D., Price W.J., and Barone F.C. Initial biochemical and functional characterization of cyclic nucleotide phosphodiesterase isozymes in canine colonic smooth muscle. J Pharmacol Exp Ther 264 (1993) 801-812
12. Guideline for Good Clinical Practice [EMEA Web site]. ICH Topic E6. European Agency for the Evaluation of Medicinal Products. Accessed March 6, 2006. International Conference on Harmonisation-World Health Organization (2002), WHO, Geneva, Switzerland. http://www.emea.eu.int Accessed March 6, 2006
13. [WMA Web site]. World Medical Association Declaration of Helsinki. Recommendations Guiding Medical Doctors in Bio medical Research Involving Human Subjects. Accessed March 6, 2006 (1989), WMA, FerneyVoltaire, France. http://www.wma.net Accessed March 6, 2006
14. Metropolitan Life Insurance Company (MLIC). Height and Weight Tables of the MLIC (1983), MLIC, Philadelphia, Pa
15. Foster J.M., Houghton L.A., Whorwell P.J., and Morris J. Altered oesophageal motility following administration of the 5-HT1 agonist, sumatriptan. Aliment Pharmacol Ther 13 (1999) 927-946
16. Levitt M.D. Production and excretion of hydrogen gas in man. N Engl Med 281 (1969) 122-127
17. Mittal R.K., and McCallum R.W. Characteristics and frequency of transient relaxations of the lower esophageal sphincter in patients with reflux esophagitis. Gastroenterology 95 (1988) 593-599
18. Johnson L.F. 24-Hour pH monitoring in the study of gastroesophageal reflux. J Clin Gastroenterol 2 (1980) 387-399
19. Richter J.E., Wu W.C., Johns D.N., et al. Esophageal manometry in 95 healthy adult volunteers. Variability of pressures with age and frequency of "abnormal" contractions. Dig Dis Sci 32 (1987) 583-592
20. Dooley C.P., Di Lorenzo C., and Valenzuela J.E. Esophageal function in humans. Effects of bolus consistency and temperature. Dig Dis Sci 35 (1990) 167-172
21. Castell D.O. Normal values for esophageal manometry. In: Castell D.O., Diederich L.L., and Castell J.A. (Eds). Esophageal Motility and pH Testing: Technique and Interpretation. 3rd ed. (2000), Sandhill Scientific, Highlands Ranch, Colo 73-87
22. Dent J., Holloway R.H., Toouli J., and Dodds W.J. Mechanisms of lower oesophageal sphincter incompe tence in patients with symptomatic gastro-oesophageal reflux. Gut 29 (1988) 1020-1028
23. Murray J.A., Ledlow A., Launspach J., et al. The effects of recombinant human hemoglobin on esophageal motor functions in humans. Gastroenterology 109 (1995) 1241-1248
24. Barham C.P., Gotley D.C., Miller R., et al. Pressure events surrounding oesophageal acid reflux episodes and acid clearance in ambulant healthy volunteers. Gut 34 (1993) 444-449
25. Hauschke D., Steinijans V.W., and Diletti E. A distribution-free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 28 (1990) 72-78
26. Bazzocchi G., Ellis J., Villanueva-Meyer J., et al. Effect of eating on colonic motility and transit in pa tients with functional diarrhea. Simultaneous scintigraphic and manometric evaluations. Gastroenterology 101 (1991) 1298-1306
27. Cann P.A., Read N.W., Brown C., et al. Irritable bowel syndrome: Relationship of disorders in the transit of a single solid meal to symptom patterns. Gut 24 (1983) 405-411
28. Jian R., Najean Y., and Bernier J.J. Measurement of intestinal progression of a meal and its residues in normal subjects and patients with functional diarrhoea by a dual isotope technique. Gut 25 (1984) 728-731
29. Lu C.L., Chen C.Y., Chang F.Y., and Lee S.D. Characteristics of small bowel motility in patients with irritable bowel syndrome and normal humans: An Oriental study. Clin Sci (Lond) 95 (1998) 165-169
30. Mittal R.K., Holloway R.H., Penagini R., et al. Transient lower esophageal sphincter relaxation. Gastroenterology 109 (1995) 601-610
31. Penagini R., Hebbard G., Horowitz M., et al. Motor function of the proximal stomach and visceral perception in gastro-oesophageal reflux disease. Gut 42 (1998) 251-257
32. Sarnelli G., Caenepeel P., Geypens B., et al. Symptoms associated with impaired gastric emptying of solids and liquids in functional dyspepsia. Am J Gastroenterol 98 (2003) 783-788
33. Sifrim D., and Holloway R. Transient lower esophageal sphincter relaxations: How many or how harmful?. Am J Gastroenterol 96 (2001) 2529-2532
34. Stanghellini V., Tosetti C., Paternicò A., et al. Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia. Gastroenterology 110 (1996) 1036-1042
35. Tack J., Piessevaux H., Coulie B., et al. Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 115 (1998) 1346-1352
36. Feinle-Bisset C., Vozzo R., Horowitz M., and Talley N.J. Diet, food intake, and disturbed physiology in the patho genesis of symptoms in functional dyspepsia. Am J Gastroenterol 99 (2004) 170-181
37. Bortolotti M., Annese V., and Coccia G. Twenty-four hour ambulatory antroduodenal manometry in normal sub jects (co-operative study). Neurogastroenterol Motil 12 (2000) 231-238
38. Duplantier A.J., Biggers M.S., Chambers R.J., et al. Biarylcarboxylic acids and -amides: Inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret. J Med Chem 39 (1996) 120-125
39. Muller T., Engels P., and Fozard J.R. Subtypes of the type 4 cAMP phosphodiesterases: Structure, regulation and selective inhibition. Trends Pharmacol Sci 17 (1996) 294-298
40. Houslay M.D., Sullivan M., and Bolger G.B. The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: Intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions. Adv Pharmacol 44 (1998) 225-342
41. Correa-Sales C., Nacif-Coelho C., Reid K., and Maze M. Inhibition of adenylate cyclase in the locus coeruleus mediates the hypnotic response to an alpha 2 agonist in the rat. J Pharmacol Exp Ther 263 (1992) 1046-1049
42. Robichaud A., Savoie C., Stamatiou P.B., et al. PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway. Neuropharmacology 40 (2001) 262-269
43. Robichaud A., Savoie C., Stamatiou P.B., et al. Assessing the emetic potential of PDE4 inhibitors in rats. Br J Pharmacol 135 (2002) 113-118
44. Souness J.E., and Rao S. Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Cell Signal 9 (1997) 227-236
45. Heaslip R.J., and Evans D.Y. Emetic, central nervous system, and pulmonary activities of rolipram in the dog. Eur J Pharmacol 286 (1995) 281-290
46. Barnette M.S. Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary dis ease (COPD). Prog Drug Res 53 (1999) 193-229
47. Barnette M.S., Christensen S.B., Essayan D.M., et al. SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: In vitro anti-inflammatory actions. J Pharmacol Exp Ther 284 (1998) 420-426
48. Rennard S.I., Schachter N., Strek M., et al. Cilomilast for COPD: Results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Chest 129 (2006) 56-66
49. Abstract. Leichtl S., Syed J., Bredenbroker D., et al. Roflumilast, a new, orally active, selective phosphodiesterase 4 in hibitor, is safe and well tolerated in patients with chronic obstructive pulmonary disease. Eur Respir 20 (2002) P1907
50. Abstract. Compton C., Duggan M., Cedar E., et al. Safety of Ariflo in a 12 month study of asthma patients. Am J Crit Care Med 161 (2000) A52